Prognostic significance of molecular alterations in human pancreatic carcinoma - an immunohistological study

被引:33
作者
Gansauge, F [1 ]
Gansauge, S [1 ]
Schmidt, E [1 ]
Muller, J [1 ]
Beger, HG [1 ]
机构
[1] Univ Ulm, Dept Gen Surg, D-89075 Ulm, Germany
关键词
pancreas; cancer; immunohistology; prognosis;
D O I
10.1007/s004230050107
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: During the last decade, many molecular alterations have been described for pancreatic carcinomas. However, the clinical and prognostic value of these alterations has been discussed and is controversial. Methods: An immunhistochemical study was performed in 82 cases of adenocarcinoma of the pancreas. Using specific antibodies, expression of EGF, EGF-receptor, cERB-B2, p53, p21(CIP1), cyclin-D1, BCL-2, CD95 and KI67 was evaluated. Results: Overexpression of the different molecules was found in 44-69% of the pancreatic carcinomas. With regard to clinico-pathological features, p53 positivity was more frequently found in advanced and undifferentiated rumours (P<0.05), EGF overexpression was significantly more frequent in advanced rumours (P<0.05) and CD95 overexpression was observed to a greater extent in undifferentiated tumours (P<0.05). Besides cyclin-D1, none of the molecules tested was of prognostic significance. Patients whose rumours expressed cyclin-D1 lived significantly shorter than patients with cyclin-D1-negative rumours. However, in subgroup analyses of patients with the same tumour stage or tumour grade, even cyclin-D1 expression had no prognostic significance. Conclusion: These results demonstrate that the prognostic significance of the molecules tested here is low. Nevertheless, with regard to tumorigenesis and tumour biology of pancreatic carcinoma, determination of molecular alterations could provide important information about pancreatic cancer.
引用
收藏
页码:152 / 155
页数:4
相关论文
共 32 条
  • [1] ALDERSON LM, 1995, CANCER RES, V55, P999
  • [2] MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES
    ALMOGUERA, C
    SHIBATA, D
    FORRESTER, K
    MARTIN, J
    ARNHEIM, N
    PERUCHO, M
    [J]. CELL, 1988, 53 (04) : 549 - 554
  • [3] BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206
  • [4] BEGER HG, 1994, CHIRURG, V65, P246
  • [5] BEGER HG, 1998, IN PRESS WORLD J SUR
  • [6] FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA
    CALDAS, C
    HAHN, SA
    DACOSTA, LT
    REDSTON, MS
    SCHUTTE, M
    SEYMOUR, AB
    WEINSTEIN, CL
    HRUBAN, RH
    YEO, CJ
    KERN, SE
    [J]. NATURE GENETICS, 1994, 8 (01) : 27 - 32
  • [7] Dergham ST, 1997, CANCER, V80, P372, DOI 10.1002/(SICI)1097-0142(19970801)80:3<372::AID-CNCR4>3.0.CO
  • [8] 2-U
  • [9] p53 expression is of independent predictive value in lymph node-negative breast carcinoma
    Fresno, M
    Molina, R
    delRio, MJP
    Alvarez, S
    DiazIglesias, JM
    Garcia, I
    Herrero, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) : 1268 - 1274
  • [10] GANSAUGE F, 1995, MED KLIN, V90, P501